Evidence map›Paper›PMID 28668723›Full record

ArticleClinical imaging

The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma.

Susanne Smolka, Julius Chapiro, Wilfred Manzano, John Treilhard, Eric Reiner, Yanhong Deng, Yan Zhao, Bernd Hamm, James S Duncan, Bernhard Gebauer and 2 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Susanne SmolkaRadiologie, Charité Universitätsmediz in Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; Yale School of Medicine, Department of Radiology and Biomedical Imaging, 333 Cedar Street, New Haven, CT 06520, USA.
Julius ChapiroYale School of Medicine, Department of Radiology and Biomedical Imaging, 333 Cedar Street, New Haven, CT 06520, USA.
Wilfred ManzanoUniversity of California, UC Irvine School of Medicine, 252 Irvine Hall, 1001 Health Sciences Road, Irvine, CA 92697-3950, USA.
John TreilhardYale School of Engineering & Applied Science, Department of Biomedical Engineering, 300 Cedar Street, New Haven, CT 06519, USA.
Eric ReinerYale School of Medicine, Department of Radiology and Biomedical Imaging, 333 Cedar Street, New Haven, CT 06520, USA.
Yanhong DengYale School of Public Health, Yale Center for Analytic Sciences, 300 George Street, Suite 555, New Haven, CT 06520, USA.
Yan ZhaoFourth Military Medical University of China, No. 169, Changle West Road, Xi'an, Shaanxi, 710032, China.
Bernd HammRadiologie, Charité Universitätsmediz in Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
James S DuncanYale School of Engineering & Applied Science, Department of Biomedical Engineering, 300 Cedar Street, New Haven, CT 06519, USA.
Bernhard GebauerRadiologie, Charité Universitätsmediz in Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
MingDe LinPhilips Research North America, 2 Canal Park, 3rd Floor, Cambridge, MA 02141, USA.
Jean-François GeschwindYale School of Medicine, Department of Radiology and Biomedical Imaging, 333 Cedar Street, New Haven, CT 06520, USA. Electronic address: jeff.geschwind@yale.edu.
Yale University · USCharité - Universitätsmedizin Berlin · DEAir Force Medical University · CNPhilips (United States) · USUniversity of California, Irvine · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Quantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver CancerR01CA206180 · NCI · YALE UNIVERSITY · PI CHAPIRO, JULIUS, DUNCAN, JAMES S · 2016 to 2025
$6.1M
See, Reach, Treat Tumor-Optimized Transarterial Chemoembolization DrugDeliveryR01CA160771 · NCI · YALE UNIVERSITY · PI GESCHWIND, JEAN-FRANCOIS H, LIN, MINGDE · 2011 to 2015
$2.6M
NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA160771NCI NIH HHS R01 CA206180NIDDK NIH HHS P30 DK034989
6 · The paper itself

Abstract

purposeTo investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria. MATERIALS AND

methodsEach of 14 patients receiving TACE and bevacizumab was matched with two patients receiving TACE alone. Baseline and Follow-up MRI was retrospectively analyzed regarding qEASL and other imaging-based criteria.

resultsPercentage-based qEASL achieved significant separation in both therapy arms (p=0.046 and p=0.015). Response and Overall Survival showed similar association among treatment groups (p=0.749).

conclusionsAnti-angiogenic therapy with bevacizumab does not impede early response assessment by qEASL.

Indexed as

Chemoembolization, TherapeuticAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabCarcinoma, HepatocellularFemaleHumansLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesTreatment OutcomeAngiogenesis InhibitorsBevacizumabAntiangiogenic agentsBevacizumabHCCqEASLQuantitative imagingTACE

Identifiers

PMID28668723
PMCPMC5720941
OpenAlexW2624074854

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.